文献速递MDS 与骨髓增殖性肿瘤白血病造血干细胞移植与细胞治疗

TP53突变等位基因频率与细胞遗传学决定MDS/AML移植预后分组

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation.
PubMed 文献 · Blood Adv · 2025-01-01

该研究分析240例接受造血干细胞移植的TP53突变MDS或AML患者,中位年龄62岁,52%为AML。以无进展生存为主要终点,发现TP53突变等位基因频率(VAF)和细胞遗传学是两项最重要的预后因素,据此可将患者分为2年PFS分别为3%、22%和60%的三组。

要点

  • TP53突变VAF≥50%者2年无进展生存仅3%。
  • VAF<50%且伴复杂/5q/7q异常者2年无进展生存22%。
  • VAF<50%且无复杂/5q/7q异常者2年无进展生存60%。

核心结论

  • TP53突变VAF和细胞遗传学可识别最可能从造血干细胞移植获益的TP53突变MDS/AML患者。

研究设计与样本

  • 分析240例接受造血干细胞移植的TP53突变骨髓增生异常综合征或急性髓系白血病患者,中位年龄62岁,52%为AML,主要终点为无进展生存。

主要发现

  • AML与MDS的移植结局相似。
  • 无进展生存的有利预后因素包括无复杂细胞遗传学/5q缺失/7q缺失、较低的VAF、monohit状态和使用全相合亲缘供者。
  • 分类与回归树分析显示VAF和细胞遗传学是两项最重要的预后因素。
  • TP53突变VAF≥50%者2年无进展生存为3%。
  • TP53突变VAF<50%且伴复杂/5q/7q细胞遗传学异常者2年无进展生存为22%。

关键数值与推荐

  • TP53突变VAF≥50%:2年无进展生存3%。
  • TP53突变VAF<50%且伴复杂/5q/7q细胞遗传学异常:2年无进展生存22%。
  • TP53突变VAF<50%且无复杂/5q/7q细胞遗传学异常:2年无进展生存60%。

临床怎么用

  • 作者认为这些数据可为临床实践提供信息,并帮助患者决定是否进行造血干细胞移植。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Results after hematopoietic stem cell transplantation (HSCT) for TP53-mutated myeloid malignancies are disappointing. Several HSCT centers decline to perform HSCT for patients with TP53 mutation because of poor outcomes. In this study, we analyzed 240 patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who underwent HSCT. We aimed to identify the patients who benefit most from HSCT. The primary outcome was progression-free survival (PFS). Of the cohort, 52% had AML and the median age was 62 years. AML and MDS outcomes were similar. We identified several favorable prognostic factors for PFS, including absence of complex cytogenetics/5q deletion/7q deletion, a lower variant allele frequency (VAF), a monohit status, and use of a matched-related donor. Using classification and regression tree analysis, we identified VAF and cytogenetics as the 2 most important prognostic factors. Patients with TP53mut VAF ≥ 50% had a 2-year PFS of 3%, and patients with TP53mut VAF < 50% and complex/5q/7q cytogenetic abnormalities had 2-year PFS of 22%. Patients with TP53mut VAF < 50% and without complex/5q/7q cytogenetics had 2-year PFS of 60%. These data inform clinical practice and help patients decide whether to pursue HSCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lontos K, Saliba RM, Kanagal-Shamanna R, et al. TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation. Blood Adv. 2025. PMID: 39853269. doi:10.1182/bloodadvances.2024014499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。